194

Dear CURE WEBMASTER:

What do we do as a people? The system (medicine, science, pharma, govts) are all in on it. They developed HIV/AIDS under the confines of 'cancer research'. The development program was called the U.S. SPecial Virus.

HIV/AIDS is the synthetic biological agent discussed in the Congressional Record, H.R. 15090, page 129. Just as we saw a "baby boom" following the alleged WWII, the United States was predicted a dimilar kind of thing in Africa, and said, we have got to do something or we will not exist.

However, what was going on at the U.S. Station for Experimental Evolution (1904)? In 1978, inside the U.S. Special Virus program, the United States confirms the 1910 bird cancer (ROUS SARCOMA) was man made.

It has been confirmed the 1918 Flu was also man made. IT killed 40,000,000.

Inside the sequences of HIV/AIDS is a nazi sgheep disease called "VISNA". In 1971, inside the U.S. Special Virus program, the United States concedes that the nazi sheep disease had not YET been associated with human disease.

In 1986, the United States concedes HIV/AIDS evolved from nazi sheep visna. See, PROC NAS Vol 83, pp. 4007 - 4011, June 1986.

The 1971 blueprint for making AIDS, the program's research logic flowchart, is ABSOLUTE evidence of the iatrogenic origin of HIV/AIDS www.boydgraves.com/flowchart.

Thank you for posting the AIDS CURE patent (abstract). We must rally the good people for the subsequent elimination of this WMD, so that we fAce not yet another. Sincerely, Boyd Ed Graves, first recipient of the AIDS CURE. www.boydgraves.com

http://www.boydgraves.com

There is an actual cases in which people have REALLY been cured of aids. One such person who is presently taking on the government is Boyd Graves. The method of production of this is revealed in U.S. patent no. 5,336,499. It is only a one time injection actually an infusion of about 20 minutes. Here is his account from: http://www.nathanielturner.com/boydgravesaidsactivist.htm

or you may visit his official website at:
http://www.boydgraves.com/

For those who are interested in buying this injection you may contact the distributor of Tetrasil or Imusil at:

http://www.marantech.com/

Well, anyway, here is one person who was cured of Aids and his account of going against the U.S. government:



Eleven years ago, Boyd Graves a lawyer and 1975 graduate of the US Naval Academy discovered he was HIV AIDS positive. Rather than lay down and accept it as a death sentence, he resolved to learn all he could about the disease in hopes of seeking a cure. What Graves discovered shocked and enraged him. Based upon information he discovered in the public domain and through the Freedom of Information Act, he concluded the US Government was involved in a super secret Special Virus Cancer Program he feels is the cause of the dreaded disease HIV/AIDS.

In 1999, Graves discovered the secret 1971 Special Virus Cancer Flow Chart which spells out the incremental development of a laboratory produced virus designed to attack and undermine the immune systems of people of African descent. Graves has sought support from various government agencies, namely, the General Accounting Office, former Ohio Congressman Trafficant, AIDS organizations and finally the courts.

On October 24, Graves will go into federal Court in San Diego California in a suit he filed in an attempt to get the US Government to 'fess up to its role in the creation of HIV AIDS.


While many have attempted to discredit and dismissed Graves' assertions, few have been able to refute the existence of the Flow Chart he discovered in 1999. The very existence of these government documents provide credence to the suspicions of many African Americans that the US Government was indeed behind the creation if HIV/AIDS.

For Graves, it has been a lonely, uphill, and often desperate battle. Not only has he had to endure charges of being a paranoid "conspiracy kook" by those who don't believe the US Government is capable of such reprehensible behavior. (They are either ignorant of or in denial about blankets laced with smallpox given to Native Americans by the US government or infamous programs like the Tuskegee Experiment where hundreds of infected African American males in Alabama were denied treatment so the US government could chronicle the long term effects of untreated syphilis.)

Graves' charges also rankle many in the academic, pharmaceutical, and public health communities who have built reputations, careers and fortunes on the orthodoxy that AIDS originated in Africa the result of human interaction with infected primates. "Indeed the truth is the HIV/AIDS enzyme is the result of a designer virus program of the United States of America and it is conclusive proof," corrected Graves, who has experienced the biases, ostracism, rejection, and government harassment due to being infected by AIDS and because he dared to expose the government's involvement in the creation of HIV/AIDS.

Nevertheless he tirelessly lectures, gives radio interviews, and speaks at conferences trying to alert the public about the government's diabolical program of population control. "We've been at this now for eleven years following my diagnosis of HIV in 1992," Graves revealed. "I didn't stick my head in the sand and as a result of that now eleven years later we have some of the official documents, even the experiments and contracts of a secret federal virus program entitled 'The US Special Virus Program'. These aren't my documents, they are the government's."

Graves is obsessed with getting the word out and sees himself as a modern day David battling the formidable Goliath of the US government. "I'm involved in a modern venue of David and Goliath because there is no more bigger giant than the United States Government. The truth provides strength. I find comfort in the truth and it gives me the drive and initiative to get up each and every day to continue our efforts to expose the truth because over time the truth has always risen to the top and its going to happen here."

Graves put the flow chart on his website www.BoydGraves.com and over 26,000 people have downloaded it. "We've got two dozen scientists and medical doctors who have reviewed this material and to a person, they all agree this federal program is at the heart of the genesis of HIV and AIDS."

Graves has a special interest in the program for he was diagnosed HIV positive. In doing his research he came upon a patented cure for AIDS which he took and now says he is symptom free.

"The United States patented the cure for AIDS in 1997 and that patent number is 5676977 and I tell people to go to www.google.com and type in U S Patent and that number and the information will come up. I tell people to go to the main library and look into the world catalogue data base and put in 'Special Virus Cancer Program' and you will find at least three four or five of those progress reports of the development of HIV are in the main library. Some of these reports are in the public domain."

Graves knows of what he speaks because he took the cure himself in 2001. "Twenty-two months ago I took the US patented cure for AIDS. It is a one time injection, I call it an infusion because it takes about twenty minutes. It's a large plunger kind of thing but that is all I've had and physically I am fine and symptom free."

Graves is eager to get the US Government in court. Earlier suits he filed were dismissed but on October 24th at 11 AM he will have his day in court to plead his case before the US Federal Court in San Diego California in his attempt to force the government to reveal the sordid details about its role in the creation of HIV/AIDS. Graves also hopes to force the government to reveal the patented cure.

Graves is a law school graduate but has not taken the bar exam in any state. Nevertheless, he will represent himself as a plaintiff seeking information on his behalf and others. "A suit can be brought by any individual. Here in this case though, we believe we have done it appropriately by being and individual who has been infected by HIV and AIDS as the lead plaintiff myself in this case going forward."

Graves is confident he will prevail in court but is disappointed in the apathy within the African?American community about the spread of this ravenous disease.

http://marantech.com/technology.htm

MARANTECH.COM

INTRODUCTION

Marantech Holding was organized in April 1999 as a Delaware limited liability company (LLC). Headquarters are in Providence, Rhode Island, USA, with additional research based in Israel.

Marantech's founder and inventor, Dr. Marvin S. Antelman, is a physical chemist known internationally for his scientific discoveries and many highly successful commercial applications (e.g., Thin Layer Chromatography used worldwide by scientists; Micro battery technology used to power credit cards and other applications; A method to eliminate deep sea corrosion of zirconium in nuclear submarine reactors).

Marantech was formed to research, develop and commercialize a unique category of inorganic compounds. All are multivalent metallic oxides that function as electron-firing molecular-scale nano devices. This class, characterized by Dr. Antelman and subsequently named ELECTRON-JUMPING COMPOUNDS® (EJC®) has broad and significant potential applications in medical, industrial and consumer markets.

A seasoned management team and distinguished consulting, medical, and scientific advisory groups are guiding the company through its current stage.

TECHNOLOGY OVERVIEW

Electron-Jumping Compounds® (EJCs) represent a class of multivalent metallic oxides that function as electron-firing molecular-scale nano devices.

To date the company has identified eight EJCs and fully patented their potential market applications. Each EJC is based on a different metallic oxide, including silver, iron, manganese, cobalt, praseodymium, terbium, copper and bismuth.

EJCs have a natural attraction to specific biochemical functional groups of the elements sulfur, nitrogen and phosphorous, one of which is expressed by certain proteins on the membrane surface of cancer cells and all rapidly proliferating pathogens (bacteria, fungi, viruses, and protozoa).

Upon contact, a multi-stage chemical reaction is triggered:

* Covalent bonding with the target
* Release of electrical energy (nano-electrocution) through a reduction/oxidation process
* Release of highly active singlet oxygen.

This action effectively ensures the target's death. No other drug or anti-microbial functions in this way. The unique method of action of the Company's compounds has the potential to establish a new class of medicine.

Below is a graphic illustration of EJC's proposed mechanism of action between TST and HIV. A similar mechanism of action is associated with the company's seven other EJCs. Depending on the target pathogen, the attracting biochemical functional group may either be sulfur, nitrogen or phosphorus.

[illustrations]

1. Close-up of HIV's membrane surface glycoprotein terminals with exposed nitrogen atoms

2. Attraction of EJC molecules (shown as tiny blue particles) to nitrogen on the virus' glycoprotein

3. Contact, covalent binding, electrocution and release of highly active singlet oxygen, through a reduction/oxidation process

4. Rapid death of the virus

Most importantly, in medical applications, normal tissues appear to be unaffected when Marantech's EJCs are applied in low, pharmaceutically effective concentrations. Additionally, what is most interesting is that because of the compound's ability to deliver an electrical shock, pathogens may be unable to develop resistance or mutation strategies. This could have profound implications for the world's health and safety and answer one of the leading problems facing today's pharmaceutical and biotech industry.

Status of Testing and Next Steps

Some of the leading contract research organizations (CROs) in the world have conducted laboratory analysis of Marantech's EJCs, including the company's most thoroughly tested EJC, Tetrasilver Tetroxide (TST™). Each CRO has provided independent assessment of its potential.

Results of in-vitro tests showed that a very wide spectrum of gram-negative and gram-positive bacteria were destroyed, including some of the leading antibiotic-resistant bacteria, viruses, protozoa and fungi in low concentrations. The independent analysis also indicated TST's ability to destroy cancer cells and inhibit their reproduction. Toxicity analysis and early-stage clinical studies have also been performed.

Several patents and patents pending protect the EJC intellectual property.

PHARMACEUTICALS

Aidance Pharmaceutical (a division of Marantech) was formed in 2002 to continue core research and fully develop the Company's compounds for systemic infectious diseases and cancer therapeutics (skin and systemic).

Infectious Diseases

Status: In independent testing, HIV, the virus that causes AIDS (Acquired Immune Deficiency Syndrome) was destroyed (98.4%) in-vitro with concentrations as low as 20 parts-per-million. Toxicity analysis in-vitro and in mice showed that the company's Tetrasilver Tetroxide (TST) does not produce toxic side effects and that healthy tissues are not effected. Because of documented non-toxicity, a limited number of terminally ill AIDS patients suffering from Wasting Syndrome, Candidiasis and P. Carinii Pneumonia have been treated in clinics outside the US. Thirty days after treatment, clinics reported an increase in patient body weight, white blood cells and other key markers.

Because TST is a broad-spectrum anti-pathogen, when administered to AIDS patients it apparently destroys many of the opportunistic infectious diseases that usually accompany HIV/AIDS.

Laboratory and clinical analysis has also documented the ability of TST to destroy the Herpes Simplex virus (HSV-1 and HSV-2) in concentrations below 96 PPM. Limited human clinical studies have produced encouraging results.

The Company expects to continue testing TST against HIV and related opportunistic infections as funding allows.

Several patents and patents pending protect the intellectual property within the areas of infectious disease.

Potential: Infectious diseases have been on the increase worldwide and show no signs of abatement. Antibiotics have no affect on viruses, and bacteria are able to mutate so effectively that Antibiotics have diminishing ability to inhibit bacterial growth. In developed countries, as many as 60% of hospital-acquired infections are caused by drug-resistant microbes. Over half of all hospitalized patients are treated with Antibiotics . Antibiotics represent a significant portion of overall healthcare costs, accounting for between 20% and 50% of total hospital drug expenditures. TST may offer an alternative to antibiotics.

More people have died from HIV/AIDS over the last twenty years than from any other disease in human history. IMUSIL® (TST formulated for intravenous use) may offer an alternative to other anti-HIV drugs (which are highly susceptible to HIV mutation, can cause severe side effects in patients, require daily dosages, and are very costly). Currently, over 40 million people worldwide suffer from this pandemic, mostly outside the US. Estimates show that a global campaign against the epidemic needs $7-10 billion annually for an effective response in low- and middle-income countries.

Because IMUSIL operates on an entirely different principle from other drugs (including antibiotics and antiretroviral drugs), the Company's compounds may offer an important alternative in the global fight against infectious diseases.

Next: Outside the US, two (2) clinical trials will be conducted in the coming months using IMUSIL against HIV/AIDS. Based on further documentation of IMUSIL's efficacy, the Company hopes to receive approval from Ministries of Health in selected countries outside the US for IMUSIL treatment.

Next steps for infectious diseases also include ongoing pre-clinical and clinical research, regulatory new drug application, expanding the medical advisory and management group, and exploring potential strategic alliances.

For additional information, please contact us.

Cancer Therapeutics

Status: A leading independent laboratory tested the effect of TST in-vitro on cultures of a variety of cancer cell lines, including human breast, colon, kidney, leukemia, liver, lung, lymphoma, melanoma, pancreas, prostate and stomach. Results from multiple testing revealed the low-concentration ability of TST to destroy these cancer cells upon contact.

Additional independent testing with TST also documented the compound's ability to inhibit the production of cervical and mammary cancer cells. Subsequent testing has confirmed TST's ability to covalently bind with cancer protein and destroy cancer cells. Marantech also contracted for an independent dermatological clinical analysis, including topical treatment of various skin and mucosal tumors with TETRASIL® (the company's topical formulation). Promising preliminary results, verified by biopsy, were reported, including apparent elimination of cancerous cells in many patients with malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, early stage cases of Paget's disease (nipple carcinoma), and cervical cancer. Results were encouraging and no adverse side effects were observed.

Several patents and patents pending protect the intellectual property within the areas of cancer therapeutics.

Potential: Scientists predict that by the year 2020 there will be 15 million new cases of cancer worldwide each year, and 10 million deaths. Cancer costs Americans alone more than an estimated $107 billion annually. TST systemic and topical therapeutic products may offer a significant alternative to existing cancer therapies.

Next: The Company is exploring strategic alliances and licensing agreements for funding and development of the company's EJC technology for cancer therapeutics.

SKINCARE & TOPICAL SOLUTIONS

Aidance Skincare & Topical Solutions (a division of Marantech) is focused on fully developing the Company's EJC technology for the treatment of non-cancerous skin conditions and diseases, including commercializing the division's topical ointment (Tetrasil®).

Status: Independent laboratory and clinical studies commissioned by Marantech indicate that topically applied TETRASIL ointment may lead to improvements in a range of infection-related skin conditions (bacterial, viral, fungal), including cold sores, genital herpes, conjunctivitis, chickenpox, shingles, diabetic leg and foot ulcers, dermal tuberculosis [mycoplasma] and ringworm. Clinical studies also indicate that TETRASIL ointment may promote healing of skin conditions that are neither cancerous nor infection-related, including atopic dermatitis (eczema), psoriasis, poison ivy, and third-degree burns, apparently by both disinfecting the area and triggering an increase in the production of new, healthy skin tissue.

In multiple tests, TETRASIL has proved to be non-toxic. Limited human use of TETRASIL by over 500 patients with some of the above-named skin conditions has produced impressive results and strong testimonials.

Several patents and patents pending protect the intellectual property topical applications of EJCs.

Potential: Several viral, bacterial, fungal and other skin conditions present vexing challenges for the medical community and patients, and TETRASIL may offer an important and timely solution.

107 million people worldwide suffer from Genital and Oral Herpes. In the last two decades, genital herpes has doubled among white adults in their 20s while increasing fivefold among white teenagers, according to the U.S. Centers for Disease Control and Prevention. Now, about one in five teens and adults (some 45 million Americans) has the disease. A recent study estimates that 49 percent of women aged 15 to 39 will be infected with herpes simplex virus type 2 by 2025 if present trends continue. The associated medical costs would rise to $2.7 billion in 2025, from $1.8 billion in 2000. Initial clinical studies and anecdotal reports indicate that TETRASIL is effective against herpes and may offer a viable alternative to current medications.

The wound care market is a $10 billion worldwide industry. In the US alone, this market was estimated to be about $3.7 billion in the year 2000, with a compounded annual growth rate of about 3%. Market data for 2001 indicate that with an estimated 6.6 million patients nationally having pressure ulcers, an estimated $5 billion is spent annually for treatment. The two main types of chronic bacterially induced wounds of concern to the Company are diabetic foot ulcers and decubital ulcers (pressure ulcers, bed sores, etc.). This is a larger market than burns or traumatic and surgically induced wounds combined. In clinical studies and patient testimonials, TETRASIL has shown efficacious results against these types of ulcers.

Next: Clinical studies for TETRASIL will continue in 2003 at selected hospitals inside and outside the US. Current pending studies are focused on pressure ulcers (bedsores) and topical human papilloma virus (HPV) and/or genital warts infection.

Sales of TETRASIL in the US have already commenced. TETRASIL is currently sold without FDA approval as a no-claim product (www.tetrasil.com). Outside the US, the Company has begun shipping TETRASIL in collaboration with key distribution partners. Approval of TETRASIL, either as a cosmetic or pharmaceutical, in selected countries outside is expected to generate modest to significant income within the next few years.

Additional next steps include ongoing laboratory and clinical research, continued commercialization of TETRASIL, FDA new drug application, as well as ongoing application with foreign ministries of health for approval of TETRASIL, and expanding the medical advisory and skincare management group.

==========================

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm
&r=1&f=G&l=50&s1=5676977.WKU.&OS=PN/5676977&RS=PN/5676977

Method of curing AIDS with tetrasilver tetroxide molecular crystal devices

US Patent Office

United States Patent 5,676,977
Inventors: Antelman; Marvin S. (Rehovot, IL)
Assignee: Antelman Technologies Ltd. (Providence, RI)
October 14, 1997
Filed: May 31, 1996

Abstract

The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans. A single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of human blood. The device molecular crystal contains two mono and two trivalent silver ions capable of "firing" electrons capable of electrocuting the AIDS virus, pathogens and ISM. When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. The devices are completely non-toxic. However, they put stress on the liver causing hepatomegaly, but there is no loss of liver function.

What is claimed is:

1. A method of treating AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject.
2. A method for increasing white blood cell counts in AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject.
3. Methods of treating AIDS-affilicted humans according to claims 1-2 where the concentration of said molecular crystals is approximately 40 PPM of the total blood weight of the human subject.

BACKGROUND OF THE INVENTION

The present invention relates to the employment of molecular crystals as anti-AIDS devices, but more particularly to the molecular crystal semiconductor tetrasilver tetroxide Ag.sub.4 O.sub.4 which has two monovalent and two trivalent silver ions per molecule, and which through this structural configuration enables intermolecular electron transfer capable of killing viruses and binding them to the resulting silver entity so that a single intravenous injection will completely obliterate acquired immune deficiency syndrome (AIDS) in humans. Furthermore, said devices are capable of killing pathogens and purging the bloodstream of immune suppressing moieties (ISM) whether or not created by the AIDS virus (HIV); so as to restore the immune system.

The present invention is based on concepts previously elucidated in applicant's U.S. Pat. No. 5,336,499 which discloses the destruction and inhibition of bacteria, algae and the AIDS virus in nutrient life supporting systems by using said silver oxide devices. Example 3 of said patent discloses that 18 PPM of said crystal devices could totally suppress the AIDS virus (page 6, line 5). Subsequent to the filing of the aforementioned patent, further testing revealed complete 100% destruction of the AIDS virus in vitro at 20 PPM, and the fact that said devices were harmless when ingested and inhaled, being non-toxic.

Encouraged by these evaluations and successes, applicant obtained permission to evaluate the crystals in vitro against murine acquired immune deficiency syndrome (MAIDS). Only one facility in the State of Israel is licensed for these evaluations, namely, the Kaplan Hospital in Rehovot, Israel, which is affiliated with the Hebrew University-Hadassah Medical School where said evaluations were done.

The initial evaluations entailed experimenting with various silver moieties cited in applicant's aforementioned patent, concentrations, non-reactive buffers and modes of administration. After about 18 months of judicious efforts and initial failures, success was finally achieved in destroying the MAIDS virus in C57BL mice with a single intravenous injection. The results of this test program comprise Example 5 of U.S. Pat. No. 5,336,499. After success with mice, the inventor was able to test the efficacy of said devices on two select etiological groups of terminal AIDS patients in a clinic in Tegucigalpa, Honduras, Central America.

The AIDS patients comprised the etiological subgroups, Candidiasis and Wasting Syndrome. Current indicator diseases for diagnosing AIDS which have been expanded by the CDC, fall into the following five major categories with the approximate percent distribution among AIDS patients:

1. P. carinii pneumonia 51%
2. Wasting syndrome 19%
3. Candidiasis 13%
4. Kaposi's sarcoma 11%
5. Dementia 6%

This invention concerns itself with the treatment and cure of candidiasis and wasting syndrome AIDS patients with Tetrasil*. These two groups account for approximately one third of AIDS cases.

*Trademark of Holipharm Corporation (of Israel) for Ag.sub.4 O.sub.4

Stedman's Medical Dictionary (Williams & Wilken's 26th Ed., 1995) defines wasting syndrome "as a condition of 10% weight loss in conjunction with diarrhea or fever . . . Associated with AIDS (p. 1744)."

OBJECTS OF THE INVENTION

The main object of the invention is to provide for a molecular scale device of a single tetrasilver tetroxide crystalline molecule capable of restoring the immunity of AIDS afflicted humans of the two AIDS etiological subgroups, candidiasis and wasting syndrome.

Another object of the invention is to provide for immunity restoration in said AIDS afflicted humans through a single injection.

Another object of this invention is to destroy ISM in humans manifesting AIDS diseases of said AIDS etiological subgroups irrespective as to whether said ISM was HIV induced, since it is known that humans may manifest AIDS and still be HIV negative, and thus restore the immune system in said humans.

Another object of this invention is to destroy the AIDS virus when present in the systems of said AIDS afflicted humans.

SUMMARY OF THE INVENTION

This invention relates to a molecular scale device not only capable of destroying the AIDS virus, but of purging the human bloodstream of pathogens and restoring immunity to AIDS patients of the candidiasis and wasting syndrome categories. Said molecular device consists of a single crystal of tetrasilver tetroxide (Ag.sub.4 O.sub.4). The crystal lattice of this molecule has a unique structure since it is a diamagnetic semiconducting crystal containing two mono and two trivalent silver ions, which in effect are capable of "firing" electrons under certain conditions which will destroy AIDS viruses, other pathogens and immune suppressing moieties (ISM), not only through the electrocution mode, but also by a binding process which occurs simultaneously with electron firing, namely, binding and chelation of divalent silver, i.e., the resulting product of the electron transfer redox that occur when the monovalent silver ions are oxidized and the trivalent ions are reduced in the crystal. The binding/chelation effect occurs at active sites of the AIDS virus, pathogens and ISM. Because of the extremely minute size of a single molecule of this crystal, several million of these devices may be employed in concert to destroy a virus colony to purge a life support system of ISM and pathogens with the consumption of only parts per trillion of the crystal devices. Thus an optimum of 40 PPM of the devices by weight of human blood was found to be sufficient to completely obliterate AIDS. This concentration is slightly over double of the optimum concentration recommended in applicant's aforementioned U.S. patent for the destruction of the human AIDS virus in vitro. Other details concerning the structure of the crystal and its mechanism against pathogens, the AIDS virus and ISM would analogously hold here, and have already been further elucidated in said patent.

=======================

DIY Silver Oxide Invention: 3x 9-volt batteries (27v DC)

http://www.pbn.4mg.com/intelreport.htm

Patented cure for HIV/AIDS mycoplasma also cures Gulf War Vaccine Infection mycoplasma, etc

http://gulfwarvets.com
http://thepowerhour.com

To all interested parties ... the following was received in response to an email I sent to the developer of this product on
2005.02.03.

STATEMENT ON TETRASIL® AND IMUSIL®

---------------------------------------------------

Thank your for your interest in Aidance products, makers of Tetrasil® Multi-Purpose Topical Ointment, www.Tetrasil.com

The Imusil® product, for treatment of HIV and AIDS, is still under development.

It is essential that the proper clinical studies be made to guarantee the treatment's efficacy and safety. Premature use, before the proper protocols are established, could jeopardize a patient's health, the product's development, and delay its introduction to the general public.

At Aidance, we certainly take very seriously the grave and compelling conditions of individuals battling HIV and AIDS. However, in order to help the most people in the safest way, we need to proceed in a responsible fashion. To achieve this, and bring the product to market, we are seeking investors, institutions, and donors to fund the proper studies and clinical trials.

If you know any potential investors (minimum $50K) who may be interested in our efforts, please refer them to us. You will be doing a great service to the world. These potential stakeholders may reach us at aht_info@marantech.com or call at (401) 223-3000. In the future, as more information becomes available, it will be published on www.Imusil.com.

Sincerely,

Aidance Management


ADDITIONAL FAQ's ANSWERED
---------------------------------------------------
Aidance has made no claims about an injectable form. We are hoping to conduct double blind clinical trials in the near future (funding dependent). There was an offshore clinical study on a "Compassionate Care" basis, of an injectable form of the active ingredient Tetrasilver Tetroxide (TsT). Even though the data gathering protocols were not followed to Aidance's satisfaction, and results were inconclusive by U.S. standards, the results were nonetheless encouraging. Imusil® is the current product now being developed with TsT for treating internal, systemic and life-threatening conditions.

Tetrasil's current formulation is to treat topical pathogens causing unwanted skin conditions only. HIV is a systemic life threatening condition beyond the scope of the Tetrasil® topical ointment. FDA approval process has not yet been sought for Tetrasil® topical ointment or the Imusil product (still under development).

Aidance is confident in the safety of the topical usage based on the success of earlier dermal, oral, ocular, ingestion toxicity and genotoxicity studies of the active ingredient, Tetrasilver Tetroxide (TsT). The success rate of TsT against a broad spectrum of pathogens for in-vitro experiments is very high. The anecdotal evidence from users of Tetrasil® is also very convincing.

While Imusil® is not yet available, the Tetrasil® product for topical application may offer significant relief to HIV and AIDS patients contending with a variety of topical skin conditions.

Thank you.

CURE MEDICATIONS FOR AIDS/HIV: INT. NGOS WRITE TO GOVT. OF NIGERIA THROUGH THE INSPECTOR GENERAL OF POLICE

Our File: NIPAD/NA/05/02/AIDS/HIV/0056 Date: February 15, 2005

CONFIDENTIAL AND LIMITED TO THE GOVERNMENT OF NIGERIA

Through:

The Inspector General of Police, Sunday Ehindero The Nigeria Police Force Headquarters Louis Edet House, Shehu Shagari Way PMB 266 Garki-Abuja

To:

Chief Olusegun Obasanjo, President of the Federal Republic of Nigeria State House, Asokoro, Abuja, Nigeria.

Alhaji Atiku Abubakar Vice- President of the Federal Republic of Nigeria State House, Asokoro, Abuja

Mr. Chris Olakpe, Deputy Commissioner of Police Force Public Relations Officer (FPRO) The Nigeria Police Force Headquarters Louis Edet House, Shehu Shagari Way PMB 266 Garki-Abuja

Governors and Senate of the Federal Republic of Nigeria c/o Presidential Research & Communications Unit Plot 1047B Usman Dan Fodio Crescent, State House, Asokoro, Abuja

Dear Sir:

ADMINISTRATION OF AIDS/HIV CURE MEDICATIONS IN NIGERIA – DIRECT ACTION PROJECT (DAP)

1. Preliminary concern:

a. I have the instructions of the International Network for Peace and Development in Africa (NIPAD) and Member NGOs worldwide to address this letter through you to the Government of the Federal Republic of Nigeria. Reason for this channel of communication is part of our report to the United Nations and member states in which we recommended that Police in Africa be involved in the program on elimination of AIDS/HIV. Another problem mitigating this channel is that the Canadian government opposed to use of the cure medications on the Blacks inside and outside Africa and the same government has conquered and ruled the Nigeria High Commission in Canada.

b. This information is brought to you under ”Life Saving Emergency Plan(LSEP) or version of DAP”, thus requiring your good office to duplicate this letter and pass it on to all the recipients within 72 hours. Now that AIDS/HIV CURE MEDICATIONS have been discovered, no Nigerian and others are supposed to die with AIDS/HIV.

c. The information available in Nigeria is WHO sources. The information has under estimated the cases for commercial and other purposes and is not current then. According to this information styled as “Facts About HIV In Nigeria, a. Percent of adults with HIV/AIDS: 5.06 %; b. Estimated number of adults with HIV/AIDS: 2,600,000; c. Estimated number of children (under 15) with HIV/AIDS: 120,000; d. Estimated AIDS deaths, 1999: 250,000; e. Reporting Period: 1979 – 1999.

d. We are not interested in this type of lecture, seminar, conference, etc type of data. We are interested in the direct action data, which related to on the spot fact. Using open and concealed cases over 3.5million victims are in Nigeria infected with AIDS/HIV. Over 0.5million victims have been killed. Our scientists and several scientists across the world believe that AIDS and HIV are MANMADE and POISON deliberately manufactured purpose of unleashing genocide against the BLACKS INSIDE/OUTSIDE AFRICA. Our scientists and several scientists across the world advised that leaders and people of Blacks nations and communities across the world should take personal action to save their people and nations from collapse and disappearance.

e. In October 2004, CURE MEDICATIONS were discovered. Under this discovery, the death of the victims of AIDS and HIV ought to have been stopped by curing the new and old victims. But the international community including the United Nations and its system; world bank, IMF, WHO, foundations, charities went underground to continue to use AIDS/HIV as business and lead to commit genocide against the Blacks. In Africa under the usual slave trade triangle or cartel, some activists have used this commerce to replace ancient slave trade.

2. DAP September 2004 and October 2004

a. Following the declaration of Continental State of Emergency on AIDS and HIV in Africa on September 11, 2004, in October 2004 series of international fora were organized by our coalition (NIPAD and Member NGOs world) on AIDS and HIV with intention to look for cure medications. The dissident and non-dissident scientists and inventors were in-attendance. After series of heated scientific debates, cures medications were found in different hidden places. The cures were invented and forced to be swept under the rug or censored for over six years.

b. The censorship mentioned was due to the fear of reprisal, which was feared by the scientists and inventors. Assessment and evaluation of the condition in Africa led to Declaration of Continental State of Emergency on September 11, 2004. The national and international pharmaceutical companies and their grantors went into hiding soon as the Continental State of Emergency was declared and EMERGENCY RESOLUTION introduced at the United Nations in September and October 2004. These processes and other campaigns empowered the scientists and inventors to come to different negotiation tables.

c. The state of emergency affects Africans inside and outside the Diaspora and African governments and their social and economic system, etc. During the negotiation, the Pharmaceutical companies/scientists were extremely humane and sympathetic about the conditions in Africa. This Godly feeling granted Africa a give away price, which will be accessible to both the poor and rich. In the US, some of the CURE MEDICATIONS are sold for $6000.00 - $7000.00 per unit. Under this kindness and after summing other costs including shipment and other expenses to Africa, $65.00 per unit was agreed by the project councils/committees for Africa. The Blacks in the US will get the unit after deducting shipment and other expenses, which were added to the units going to Africa. The reason for this low price for the Blacks in the United States of America is that some of the scientists, inventors and their chemists and pharmaceutical companies are located in the United States of America.

d. Take further notice that the implementing councils and committees resolved that 100% of all Africans AIDS and HIV must get one unit of the cure medications. It takes one unit to eliminate AIDS and HIV completely and permanently in the body.

3. Example of the Cure Medications: Tetrasilver Tetroxide Molecular Crystal Medications and Capacity to Eliminate AIDS and HIV Completely in Human Body:

a. For example, Tetrasilver tetroxide is one of the five (5) AIDS and HIV cures which the selection committees/councils selected in October 2004 out of the 23 scientific inventions submitted by AIDS and HIV scientists under ad hoc international conference fora. It is organized ad hoc or secret because of the alleged fear as result of the threat unleashed here and there internationally by certain pharmaceutical companies and their sponsors or grantors.

b. The medications are insoluble and it remains embedded in tissues as free molecules and as microscopic aggregates. The particle surface acts, as supra oxidation-reduction catalyst that cleans the body of viral activity without causing any unwanted long-term and short-term side effects.

c. The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans.

d. A single intravenous injection of the medications is all that is required for efficacy at levels of about 40 PPM of human blood. The medication molecular crystal contains two mono and two trivalent silver ions capable of "firing" electrons capable of electrocuting the AIDS virus, pathogens and ISM.

e. When administered into the bloodstream, the medications electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties, which chelate and bind active sites of the entities destroying them. The mediations are completely non-toxic.

f. On February 16, 2005 one of the Presidents of the Cure Pharmaceutical Companies said to settle certain scientific debate and inquiries,

“It may be of interest to you to know that one of the eulogies delivered at the burial ceremony of Mandela's son who died of AIDS, was Paul Gama...a prominent member of Zulu Community...Paul's brother Joseph took Imusil nearly 4 years ago and was completely cured of AIDS along with 4 others; at a S. African clinic.”

g. In October 2004 and November 2004 Dr. Phillip Ofume received confidential message regarding the late son of Ex-President Nelson Mandela. The informant placed the message under top secret and pleaded that her/his life would be in danger. Dr. Ofume sent two messages to President Mandela and promised to issue two or one doses gratis to him for his son. Did the messages go through to President Mandela is question of investigation now.

4. Specimen Treatment/Cure Prior to Funding:

a. To secure confidence and trust, all financiers/grantors or countries within the humanitarian plan desiring to fund the project are permitted to recommend one full blown out AIDS/HIV Patient with Positive Test certificate to receive free treatment/cure. The cure medications have been administered inside and outside Africa (including the United States of America).

b. The Scientists/Inventors/Chemists have agreed to mass-produce the devices in accordance with the international humanitarian legislation affordable to governmental and non-governmental AIDS and HIV organizations and agencies including the so called poor nations and peoples.

5. Project and Implementation

a. The cure and prevention education aspects will be handled in association with the Departments of Health and Education in Nigeria. We will recommend only one week training for the within staff and enter into durable consultation agreement with the communities to facilitate transition from the pilot project to expanded health and education delivery programs.

b. To remove scare to report new and old cases and facilitate treatment, AIDS/HIV hospital, clinic and pharmacies will be separated. Nigeria and other African countries will be zone into treatment region.

6. Production and Supply Potential

a. We will be able to supply 4million doses within two months from the date order is made.

b. The delivery will be carried out immediately and landing will be within the same period of two months for the communities inside the United States of America.

c. Review of the negotiation mentioned above will incorporate the Government of Nigeria and the scientists and pharmaceutical companies.

7. Fact relating to the Research/Invention and Discovery of the Cure Medications:

a. In Africa during the research and investigation, the INTERNATIONAL NETWORK FOR PEACE AND DEVELOPMENT IN AFRICA (NIPAD) and member NGOs encountered face to face, the scourge and horror of AIDS and HIV with shock, stress and overwhelming trauma after seeing and reviewing uncountable deaths, dying bodies, scare imbued life threatening illnesses and the drifting of entire people and continent towards AIDS and HIV base extinction and genocide conditioned in the nature of total human cleansing, never seen in human society and history.

b. Effective the 11th Day of September 2004, NIPAD and member NGOs worldwide declared CONTINENTAL STATE OF EMERGENCY in AFRICA. Thereafter, they introduced EMERGENCY RESOLUTION at the United Nations and also submitted the Resolution to countries, NGOs, etc. including recipients in this letter. The complete texts in book format of the Resolution and Continental State of Emergency have been served on the President of the Federal Republic of Nigeria through the Nigeria High Commissioner to Canada Ambassador Femi George and the same located at www.nipad.org.za. Mr. President of Nigeria did you receive these books?

c. The decision leading to the Declaration of State of Emergency in Africa is embedded in the conclusion of over five years direct discovery examination, research, investigation and inspection in Africa on AIDS and HIV all of which was entered into humanitarianly in accordance with the United Nations Universal Declaration of Human Rights (December 10, 1948) Article 1 (et al).

d. Since the birth of AIDS and HIV and devastating effect on human particularly in Africa, the five cures, which were selected in October 2004, out of 23 scientific inventions submitted across the world for consideration, are the FIRST AND ONLY OUTSTANDING CURES invented by scientists and scientific inventors in the world, which have the capacity to cure or eliminate AIDS and HIV permanently in human body. To perpetrate genocide in Africa or against the Blacks, the cures were forced to remain secret and tactically censored by the national and international pharmaceutical companies and their grantors.

8. Imposed dangerous and deadly AIDS/HIV treatment in Africa - ARVs (Anti-retroviral drugs)

a. All international AIDS conferences, seminars, symposia, films, DVD, movies, lectures, etc 1980 – present began with ARVs (Anti-retroviral drugs) and ended with more ARVs and more ARVs and horrors of the sick and dying Blacks (and) without measures to save the lives of the sick and dying Blacks(and). The meaning of this is more death more funding and more empire or profit returns to these actors.

b. Anti-retroviral drugs (ARVs) offer no cure for AIDS.

c. The toxic effects of ARVs include nerve damage, weakened bones, cancers, unusual accumulation of fat in the neck and abdomen and drug-induced diabetes.

d. Without curing the end-illnesses or AIDS and HIV, many users of ARVs have developed dangerously high levels of cholesterol and other lipids in the blood, raising concern that HIV positive persons might face another epidemic of heart disease thus, setting close pace for their mass death.

e. Without curing the end-illnesses or AIDS and HIV, indiscriminate use of ARVs to pregnant mothers is fraught with danger and harm of early death before other AIDS and HIV victims.

f. The AIDS and HIV as poison and Alternativa scientists cautioned specifically that “if a cigarette smoking mother can deliver a ‘blue baby’, if an alcoholic mother can deliver a ‘drunk child’, if thalidomide can produce ‘monster babies’, you are unwittingly playing with the future generation by demanding that the HIV positive mother be given ARVs compulsorily.”

g. Before the discovery of these cures, all the prescribed AIDS and HIV medications inside Africa do not cure AIDS and HIV. All the drugs prescribed for Africa, which number over 200 within the drug category of the anti-retrovirals medications and dangerously used as preventive measure either by vaccines and other means. Anti-retrovirals medications do not cure and prevent AIDS AND HIV. These dangerous drugs and injections (anti-retrovirals medications) are used under complex process in combination with other anti-retrovirals drugs/injections because of the resistance concerns in which they are designed to kill one (pregnant woman) and save one child (baby) . The one child (baby) saved later dies before the age of seven (7) thereby increasing the number of “death and temporary orphans” which die latter-day.

g. We restate that the NGOs and others inside and outside Africa have commercialized the business of anti-retrovirals medications to enjoy the longevity of the profit accruing out from this shady and evil business and maintain the drive for genocide and racial cleansing against Africa and Blacks. Heartlessly, campaign for the awareness of the cures, have been suppressed by the international foundations, charities and other granting NGOs and GOs. Some of these international foundations, charities and other granting NGOs and GOs (names protected) have denied funding for meeting for the on-the-spot test of the cures in Africa. If grant to facilitate important meeting on program to save lives is denied what hope is expected on grant for the purchase of the cure medications. These mini-gods cannot block Good Samaritans like the NIPAD and Member NGOs that are dedicated and covenant to the call to duty to save the lives of over 50million victims with AIDS and HIV inside and outside Africa. The petition to Mr. and Mrs. Bill & Melinda Gates Bill & Melinda Gates Foundation is located at: http://groups.google.com/groups?hl=en&lr=&q= author:federr007%40hotmail.com+

Yours very truly, For: NIPAD, Member NGOs, Implementing Committees/Councils and Representatives

Phillip Ofume, Ph.D. International Coordinator

NIPAD, Member NGOs, Implementing Committees/Councils and Representatives:

INTERNATIONAL COUNCIL ON CONTINENTAL STATE OF EMERGENCY IN AFRICA COMMITTEE ON INTERNATIONAL RESOLUTION ON ELIMINATION OF AIDS AND HIV

INTERNATIONAL POLICY RESEARCH COUNCIL AND PROJECT DEVELOPMENT PROGRAM

INTERNATIONAL AMALGAMATED COUNCIL OF SCIENTISTS AND SCIENTIFIC INVENTIONS/INVENTORS ON AIDS AND HIV

JOINT INTERNATIONAL IMPLEMENTING COUNCIL OF SCIENTISTS AND COLLABORATING PROFESSIONS

Representatives:

1. DR. PHILLIP C. OFUME

2. MR. OKOLOEZE U. JONATHAN

3. REV. (DR.) MARKTONY KORIEOCHA

4. MR. EZEJI CHIJI

5. DR. KRIS KIFINDI BUNKHETI

6. DR. ED BOYD GRAVES

7. DR. JOSEPHINE OKEI ODUMAKIN

8. DR. GODSON ETIEBET

9. MR. ADEMUYIWA DAVID

10. DR. TAN OCHOLLU

11. DR. REID MACDONALD

ETC.

Contact Information:

International Network for Peace and Development in Afrik (Africa - NIPAD) International Headquarters 238, Central House 278 Pretorius Street, CNR Central and Pretorius Street P.O.Box 4732 Pretoria 001 South Africa. 10/10 Tel/ Fax: 27-123277881 Cell.: +27 83 42 12390; Other International Telephone/Fax/Cell: Tel.: +902-832-3559 Fax: +902-832-3558 Cell: +902- 452-5617 Cell: + 902-209-6758 E-mail: info@nipad.org.za,africasuccourersorgans@yahoo.co.in, ,federr008@yahoo.ca,aids_cureinstant@yahoo.ca, pofume@ns.sympatico.ca Website: www.nipad.org.za

TEST DATA

To date, most of the Company’s testing of compounds for pharmacological safety and efficacy has centered on Tetrasilver Tetroxide (TST). Several of the largest contract research organizations in the world (Quintiles, Parexel, MDS/Pharma and others) have conducted laboratory evaluation of the compound and provided independent assessment of its performance potential.

Efficacy and non-toxicity has been assessed through initial in-vitro and clinical testing.

Results of in-vitro tests commissioned by Marantech strongly suggest that TST molecules selectively target and kill rapidly proliferating bacteria, viruses, fungi, protozoa, and cancer cells. Specifically, the tests showed that a very wide spectrum of gram-negative and gram-positive bacteria was destroyed, including several of the leading antibiotic-resistant bacteria, viruses, protozoa and fungi in concentrations ranging between 0.50 and 96.00 parts-per-million. Independent testing has also indicated the compound’s ability to inhibit the production of a wide range of cancer cells.

http://www.marantech.com/testdata.htm

Tuesday, December 07, 2004
Imusil® - Aids cure and a whole lot more

[hypothesis]

This here visionary philosopher is going on record
to state that this medication, if it ever gets widely
produced, will destroy the anti-biotics industry.

One injection of Imusil will kill virtually every
pathogen suffered and known to man and then some.

The FDA will not approve it so all legal injections
will have to be done outside the US. I'm talking
about one injection or IV treatment for the
complete cure. I expect an injection directly into
cancerous tumors will be needed to kill them.

[/hypothesis]

More people have died from HIV/AIDS over the
last twenty years than from any other disease in
human history. IMUSIL® (TST formulated for
intravenous use) may offer an alternative to
other anti-HIV drugs (which are highly
susceptible to HIV mutation, can cause severe
side effects in patients, require daily dosages,
and are very costly). Currently, over 40 million
people worldwide suffer from this pandemic,
mostly outside the US. Estimates show that a
global campaign against the epidemic needs $7-10
billion annually for an effective response in low-
and middle-income countries.

Because IMUSIL operates on an entirely different
principle from other drugs (including Antibiotics
and antiretroviral drugs), the Company's
compounds may offer an important alternative in
the global fight against infectious diseases.

original post at:
http://djomama.blogspot.com/2004/12/imusil-aids-cure-and-whole-lot-...

http://djomama.blogspot.com/2004/12/imusil-aids-cure-and-whole-lot-...

THURSDAY, DEC 09, 2004

From: IMPY@NETVISION.NET.IL
Marvin

To: jomama
Subject: Fw: Imusil Inquiries.


Date: Thu, 09 Dec 2004 13:38:31 -0800

STATEMENT ON TETRASIL® AND IMUSIL®
-------------------------------------------------

Thank your for your interest in Aidance
products, makers of Tetrasil® Multi-Purpose
Topical Ointment, www.Tetrasil.com

The Imusil® product, for treatment of HIV and
AIDS, is still under development.

It is essential that the proper clinical studies
be made to guarantee the treatment's efficacy and
safety. Premature use, before the proper
protocols are established, could jeopardize a
patient's health, the product's development, and
delay its introduction to the general public.

At Aidance, we certainly take very seriously the
grave and compelling conditions of individuals
battling HIV and AIDS. However, in order to help
the most people in the safest way, we need to
proceed in a responsible fashion. To achieve
this, and bring the product to market, we are
seeking investors, institutions, and donors to
fund the proper studies and clinical trials.

If you know any potential investors (minimum
$50K) who may be interested in our efforts,
please refer them to us. You will be doing a
great service to the world. These potential
stakeholders may reach us at
aht_info@marantech.com or call at (401) 223-3000.
In the future, as more information becomes
available, it will be published on www.Imusil.com.

Sincerely,

Aidance Management



ADDITIONAL FAQ's ANSWERED
-------------------------------------------------
Aidance has made no claims about an injectable
form. We are hoping to conduct double blind
clinical trials in the near future (funding
dependent). There was an offshore clinical study
on a "Compassionate Care" basis, of an injectable
form of the active ingredient Tetrasilver
Tetroxide (TsT). Even though the data gathering
protocols were not followed to Aidance's
satisfaction, and results were inconclusive by
U.S. standards, the results were nonetheless
encouraging. Imusil® is the current product now
being developed with TsT for treating internal,
systemic and life-threatening conditions.

Tetrasil's current formulation is to treat
topical pathogens causing unwanted skin
conditions only. HIV is a systemic life
threatening condition beyond the scope of the
Tetrasil® topical ointment. FDA approval process
has not yet been sought for Tetrasil® topical
ointment or the Imusil product (still under
development).

Aidance is confident in the safety of the
topical usage based on the success of earlier
dermal, oral, ocular, ingestion toxicity and
genotoxicity studies of the active ingredient,
Tetrasilver Tetroxide (TsT). The success rate of
TsT against a broad spectrum of pathogens for in-
vitro experiments is very high. The anecdotal
evidence from users of Tetrasil® is also very
convincing.

While Imusil® is not yet available, the
Tetrasil® product for topical application may
offer significant relief to HIV and AIDS patients
contending with a variety of topical skin
conditions.

Thank you.

Clinical Experiments Show Silver Compound Can Help AIDS Patients: Researchers Say Silver Oxide Offsets AIDS Loss of Immune Response


By Samuel Etris, Senior Technical Consultant to The Silver Institute


One dose of silver oxide may prolong the life of terminally ill patients suffering from AIDS, according to a study conducted at an AIDS clinic in Central America. The triple-charged silver in silver oxide appears to significantly increase the effectiveness of silver in combating disease-prone bacteria and viruses that rage through an AIDS-infected patient. This action of silver offsets the loss of the body's bacteria-fighting immune system caused by the AIDS virus.

The ten patients classified as terminally ill at The Struggle Against AIDS Clinic, Comayaguela, Honduras, were treated with polyvalent silver oxide. The ten patients fell into two of the major AIDS categories: Wasting Syndrome and Candidasis, which covers approximately one third of all AIDS cases.

Before the administration of one single dose of polyvalent silver oxide (approximately 40 parts per million of blood volume), the patients were removed from the standard AZT therapy. Following the administration of polyvalent silver oxide, eight out of nine patients showed an increase in their white blood count from 10 to 350 percent. Then they were treated with the standard Antibiotics .

Two of the patients had conditions so far advanced that they were unresponsive to the subsequent treatment and succumbed within a year. However, the single treatment appeared to prolong the lives of the eight remaining patients as much as three years. This single experiment shows the promise for the polyvalent silver oxide regimen.

Further research is needed to investigate the optimal modes of administration and dosages of the polyvalent silver oxide for AIDS therapy. Additional clinical trials are now being organized in South Africa to gain more data on its potential.

For more than a century, single-charged silver has been a proven barrier against blindness in babies' eyes exposed to disease during birth. The single-charged silver replaces the working hydrogen atoms of bacteria and extracellular viruses that supply the energy to function. Blocking the energy supply inactivates them. The more powerful triple-charged silver in polyvalent silver oxide signals new potential in combating disease.

In one laboratory experiment, polyvalent silver oxide in as little a concentration as 20 parts per million inserted into cultured HIV-1 infected cells resulted in a 98.4-percent kill. This breakthrough, reported by the National Virology Laboratory of Israel at Tel HaShomer, encouraged the Kaplan Hospital, Rehovot, Israel, to conduct a study of laboratory mice infected with Murine AIDS. A single administration of 40 parts per million of polyvalent silver oxide (Ag4O4) reportedly resulted in an effective cure.

These early experiments with AIDS infections indicate that polyvalent silver oxide may be more than merely a multi-spectrum Antibiotic inactivating a whole range of bacteria, such as candida albicans, that ravage the AIDS-weakened immune system. Further studies may reveal that silver also stimulates the body's immune system to restore at least some of its normal function, aiding in the patient's recovery.

For nearly a decade, Antelman Technologies, Inc., Rehovot, Israel, has been conducting laboratory and clinical studies to determine the effectiveness of polyvalent silver oxide for a wide variety of applications. Currently it is available over the counter as the EPA-approved product Sildate, which replaces chlorine in swimming pools, U.S. patents for which have been assigned to the supplier, N. Jonas & Co. in Bensalem, Pennsylvania.

The buffer to bring polyvalent silver oxide into an injectable solution for clinical evaluation is supplied by Holipharm Corp., in Jerusalem, which has received the assignment of all rights of U.S. patents for (Ag4O4) AIDS studies under the trade name Tetrasil.

Silver News - February/March 1998

original text::
http://www.silverinstitute.org/news/2a1998.htm

http://www.silverinstitute.org/news/2a1998.htm

From TheCosmicDetective@youtopiainstitute.com Thu Jan 24 23:00:58 2002
Date: Fri, 25 Jan 2002 01:12:08 -0000
From: thecosmicdetective
To: cancercure@yahoogroups.com
Subject: [cancercure] A CURE for HIV/AIDS?

YOUtopia INstitute www.YOUtopiaINstitute.com

FOR IMMEDIATE RELEASE


San Diego, CA. - January 24, 2002 (YOUtopia INstitute)-With the fact
in mind that genuine "Faith Based Initiative" is crucially important,
we are convinced that the matter is far too important to wait
for "The President" and the US Congress to pass some legislation and
allocate some money. Our non-profit, spiritual priority YOUtopia
INstitute is moving forward to help neutralize the most sinister and
devastating bioterrorism attack on the human species in the history
of humankind on this earth. ( www.boydgraves.com/comments/ )

- BACKGROUND for helping as many people as we can, who are infected
with the AIDS/HIV virus, to receive the required one time injection
of TETRASIL, tested and USTetrasilPatent as a "Method of curing
AIDS..."

1. Boyd E. Graves, J.D. who was infected with the AIDS/HIV virus
ten years ago, now dubbed "The Alpha Man," for having been,
officially, the first AIDS/HIV infected person from the US to receive
an injection of Tetrasil, on November 19, 2001.

a. Laura and Rama are witnesses to the remarkable and incredible,
overnight and on going, improvement in Dr. Graves' energy level
and physical appearance.

b. Upon returning to Cleveland after taking the injection of
Tetrasil, Dr. Graves had tests done at the Cleveland Veteran's
Administration Hospital. Those test results showed that after two
weeks his T cell count had increased by 74%, and that his blood
pressure rate was that of a 25 year old.

c. Two months later the improvement in his physical health, in
general, as well as his relief from years of constant pain, extremely
low vitality and energy level continues. He's now doing a little
jogging, playing a bit of tennis and doing one armed push ups.

We have in the past several months given spiritual and mental
support, as well as provided financial assistance to Boyd E. Graves,
J.D., this earth's leading researcher into the origin of
AIDS/HIV, legal advocate for the people and author of "State
Origin: The Evidence of the Laboratory Birth of AIDS"
www.BoydGraves.com


Dr. Graves has been the featured guest on our The Cosmic D-Laura Show
three times since November 2001, and changed his permanent residence
from Cleveland and Youngstown Ohio here to San Diego, California in
December 2001.

We have begun a cooperative association with Dr. Graves to provide
for him, use of our office space and equipment, and a YOUtopia
INstitute e-mail address. Additionally, Dr. Graves will shift roles
from featured guest to "Guest Host" of our The Cosmic D-Laura
Show on-line talk radio broadcast.

Our primary priority goals, plans and intentions for the year 2002
have to do with the practical application of available solutions for
the major problems effecting human kind and the over all desirable
quality of life on Earth/Gaia. Starting with providing liaison to
people infected with AIDS/HIV to receive the required one-time
injection of Tetrasil.

- PLAN

1. To announce and inform about the available opportunity for
YOUtopia INstitute and Boyd `Ed' Graves, J.D. to make all of
the necessary arrangements for anyone infected with the AIDS/HIV
virus to receive the required one time injection of Tetrasil, tested
and US patented USTetrasilPatent as a "Method of curing AIDS"

2. To broadcast on the World Wide Web/Internet, at least three times
per week for up to three hours each, The Cosmic D-Laura Show devoted
solely to presenting this information to as many people as we can
reach.

3. To provide on going updates, on The Cosmic D -Laura talk radio
broadcast, in newsletters and postings, on Dr. Graves laboratory test
results, T cell count, etc. as well as direct consultation with Dr.
Graves by e-mail, telephone, fax and/or in person.


For Additional Information Contact:

E-mail: CosmicD@YOUtopiaINstitute.com
BoydEGraves@YOUtopiaINstitute.com

Web site: www.YOUtopiaINstitute.com www.BoydGraves.com

Telephone: 619/584-0542 Fax: 619/269-4561

AIDS Is Man-Made Interview with Dr. Boyd Graves The Final Call, Sultan Muhammad, Oct 31, 2004
(EXCERPT)...

SM: Your research reports that there was/is a cure for AIDS.

BG: Absolutely. The Flow Chart has five phases. In Phase IV A are immunological controlled experiments where they developed the inhibitors, the vaccines, as well as the cure for HIV/AIDS before it was released. There is a cure for AIDS patented in, I believe, October 1997, a one-time injection that eradicates the HIV/AIDS in the blood system without any side effects.

SM: Were you diagnosed with AIDS?

BG: I had a diagnosis. There is some speculation that it might even have been false-positive. There are many conditions. One of the conditions that I had at that time allowed, for Black people in particular, to test false-positive for HIV/AIDS, whereby you were placed on medicines with tremendous side effects. These medicines led to liver failure that killed a number of persons. In November 2001, I took the U.S. patented cure and, for the last 33 months from a physical standpoint, have been in the midst of rejuvenation. Therefore, we do know that the cure is available; it works; we believe it is suppressed simply because not enough people have been killed yet.

SM: What is this cure called?

BG: Tetrasil. It has a second name, which is Imusil. The patent number is 5676977.

SM: Who has the patent on this drug?

BG: The patent was issued to Rabbi Dr. Marvin Antelman of Morantech Corporation in Providence, Rhode Island. In my research and contact with Rabbi Dr. Antelman, he told me he had a college relationship with Dr. Gallo, who had stolen something that he and others had been working on. That led me to think that perhaps Dr. Antelman was given the AIDS cure as a payback by Dr. Gallo. There is a connection between the AIDS invention and the AIDS cure patent program. There is a tetra silver that is used in swimming pools. We found a similarity of the blood in your body with respect to the water in a swimming pool. If you put something in a disc in your swimming pool, then all the water becomes clear. The same is true with this one-time injection of purifying the blood in the body. The process is identical to how you purify the water in the swimming pool, and I believe that the swimming pool product is called tetra silver. Dr. Antelman changed the name from Tetrasil to Imusil.

SM: Who is Dr. Vincent Gammil?

BG: Dr. Gammil is a friend of mine who led me to the Tetrasil. He was also instrumental in supervising Dr. Roberto Munoz, of Mexico, when I received the injection in November 2001.

SM: Did you receive the injection in Mexico?

BG: No, I received it in Southern California.

SM: How were you able to get the drug?

BG: The chemical composition of the Tetrasil is Ag4O4 (Silver 4/Oxygen 4). It is a relatively simple compound to make. We could flood Africa with it and bolster the individuals who are suffering and laboring under the throes of HIV and AIDS, so that we have a chance to save the continent. As we speak, the first trials of the cure, Tetrasil, have gotten underway, with only three individuals in Kinshasa taking the injection. A recent report was that the individuals are doing well and are delighted to have had the AIDS cure. Therefore, we know it works and we know that it is suppressed.

SM: Thank you.

(Dr. Graves earned his Juris Doctor degree from the Ohio Northern University College of Law in May 1993, almost 20 years after receiving a B.S. degree in Engineering from the U.S. Naval Academy in Annapolis, Maryland in 1975. He has been a Director of AIDS Concerns for the international medical research foundation, Common Cause, headquartered in Sudbury, Ontario, Canada for the last five years. For more information, visit www.boydgraves.com.)

FULL INTERVIEW AND MORE INFORMATION CAN BE FOUND AT:
http://www.nothingnewunderthesun.org/aids.htm

http://www.nothingnewunderthesun.org/aids.htm